Kerstin Schäfer‐Eckart

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

Christoph Röllig, Hubert Serve, Andreas Hüttmann et al. · The Lancet Oncology · 2015 · 395 citations · Full text

Sorafenib Versus Placebo, Hematological Malignancy, Oncology +9

Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial

Martin Bornhäuser, Joachim Kienast, Rudolf Trenschel et al. · The Lancet Oncology · 2012 · 269 citations

Hematological Malignancy, Versus Standard Conditioning, Transplantation +11

Long-Term Prognosis of Acute Myeloid Leukemia According to the New Genetic Risk Classification of the European LeukemiaNet Recommendations: Evaluation of the Proposed Reporting System

Christoph Röllig, Martin Bornhäuser, Christian Thiede et al. · Journal of Clinical Oncology · 2011 · 262 citations · Full text

Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's Lymphoma

Andreas Josting, Horst Müller, Peter Borchmann et al. · Journal of Clinical Oncology · 2010 · 160 citations · Full text

<i>CEBPA</i> mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

Franziska Taube, Julia Annabell Georgi, Michael Krämer et al. · Blood · 2021 · 159 citations · Full text